Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections. The company is also develops GEN-009, which is in pre-clinical stage to treat neoantigen cancer; GEN-010 that is in pre-clinical stage for the treatment of patients in second generation neoantigen cancer; GEN-007, which is in research stage to Epstein-Barr virus; and GEN-006 that is in research stage for the treatment of immune-oncology-tumor-associated antigen cancer. It license agreement with University of California and Harvard University; and collaboration agreement with Novavax, Inc. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.